Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education.
Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.
In this episode, Dr. Gandhi discusses topline results from several studies investigating weight gain and metabolic outcomes with different antiretroviral therapy (ART) regimens among patients with HIV, including lipid level changes, cardiovascular disease risk, diabetes risk, and metabolic syndrome risk. The overview will include analyses from:
In addition, Dr. Gandhi reviews new information on biomedical prevention of HIV infection, including results from several preclinical trials, a study investigating real-time urine-based testing for tenofovir levels, and the latest safety data from the phase III DISCOVER trial comparing FTC/TDF vs FTC/TAF for daily oral HIV pre-exposure prophylaxis (PrEP) among cis-gender men who have sex with men (MSM) and transgender women.
Content based on an online CME program supported by independent educational grants from Gilead Sciences; Merck & Co., Inc.; and ViiV Healthcare.
Link to full program: https://www.clinicaloptions.com/hiv/conference-coverage/retroviruses-2020
Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
University of California, San Francisco
Ward 86 HIV Clinic
San Francisco General Hospital
San Francisco, California
Senior Scientific Director
Executive Vice President
This program has been made available online.
Clinical Care Options (CCO): South African patient’s perspective on living a full life with her HIV diagnosis, long-term ART, and HIV activism
Clinical Care Options (CCO) patient audio: Yvette Raphael provides her perspectives and advice as an individual living with HIV
Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)